248 related articles for article (PubMed ID: 28054978)
41. Hemoglobin-based oxygen carriers in trauma care: scientific rationale for the US multicenter prehosptial trial.
Moore EE; Cheng AM; Moore HB; Masuno T; Johnson JL
World J Surg; 2006 Jul; 30(7):1247-57. PubMed ID: 16710614
[TBL] [Abstract][Full Text] [Related]
42. Oxygen carriers ("blood substitutes").
Topfer LA; Hailey D
Issues Emerg Health Technol; 2001 Jul; (21):1-6. PubMed ID: 11776287
[TBL] [Abstract][Full Text] [Related]
43. Structural basis for the potent antisickling effect of a novel class of five-membered heterocyclic aldehydic compounds.
Safo MK; Abdulmalik O; Danso-Danquah R; Burnett JC; Nokuri S; Joshi GS; Musayev FN; Asakura T; Abraham DJ
J Med Chem; 2004 Sep; 47(19):4665-76. PubMed ID: 15341482
[TBL] [Abstract][Full Text] [Related]
44. Impact of acellular hemoglobin-based oxygen carriers on brain apoptosis in rats.
Vandegriff KD; Malavalli A; Lohman J; Young MA; Terraneo L; Virgili E; Bianciardi P; Caretti A; Samaja M
Transfusion; 2014 Aug; 54(8):2045-54. PubMed ID: 24673504
[TBL] [Abstract][Full Text] [Related]
45. Hemoglobin-based oxygen carriers: a long road from bench to bedside.
Quirolo K
Pediatr Hematol Oncol; 2007 Sep; 24(6):461-3. PubMed ID: 17710665
[No Abstract] [Full Text] [Related]
46. Microparticle, nanoparticle, and stem cell-based oxygen carriers as advanced blood substitutes.
Tao Z; Ghoroghchian PP
Trends Biotechnol; 2014 Sep; 32(9):466-73. PubMed ID: 24929580
[TBL] [Abstract][Full Text] [Related]
47. Microvascular and systemic responses to novel PEGylated carboxyhaemoglobin-based oxygen carrier in a rat model of vaso-occlusive crisis.
Nugent WH; Jubin R; Buontempo PJ; Kazo F; Song BK
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):95-103. PubMed ID: 30739524
[TBL] [Abstract][Full Text] [Related]
48. Preclinical In Vitro Safety Investigations of Submicron Sized Hemoglobin Based Oxygen Carrier HbMP-700.
Kao I; Xiong Y; Steffen A; Smuda K; Zhao L; Georgieva R; Pruss A; Bäumler H
Artif Organs; 2018 May; 42(5):549-559. PubMed ID: 29508415
[TBL] [Abstract][Full Text] [Related]
49. [Sickle cell anemia and the affinity of the blood for oxygen].
Pocidalo JJ; Sinet M
C R Seances Soc Biol Fil; 1979; 173(2):303-13. PubMed ID: 159755
[TBL] [Abstract][Full Text] [Related]
50. New transfusion strategies: red cell substitutes.
Winslow RM
Annu Rev Med; 1999; 50():337-53. PubMed ID: 10073282
[TBL] [Abstract][Full Text] [Related]
51. Blood substitutes as pharmacotherapies in clinical practice.
Jahr JS; Walker V; Manoochehri K
Curr Opin Anaesthesiol; 2007 Aug; 20(4):325-30. PubMed ID: 17620840
[TBL] [Abstract][Full Text] [Related]
52. Toxicities of hemoglobin solutions: in search of in-vitro and in-vivo model systems.
Buehler PW; Alayash AI
Transfusion; 2004 Oct; 44(10):1516-30. PubMed ID: 15383027
[TBL] [Abstract][Full Text] [Related]
53. [Blood substitutes: state of the art and technical setbacks and why we are still disappointed].
Vigneron C; Smani Y; Faivre B
Bull Acad Natl Med; 2007; 191(4-5):837-47; discussion 847. PubMed ID: 18225438
[TBL] [Abstract][Full Text] [Related]
54. Hydroxyurea in the treatment of sickle-cell anemia.
Howard LW; Kennedy LD
Ann Pharmacother; 1997 Nov; 31(11):1393-6. PubMed ID: 9391697
[TBL] [Abstract][Full Text] [Related]
55. X-ray crystallography and sickle cell disease drug discovery-a tribute to Donald Abraham.
Donkor AK; Pagare PP; Mughram MHA; Safo MK
Front Mol Biosci; 2023; 10():1136970. PubMed ID: 37293554
[TBL] [Abstract][Full Text] [Related]
56. The development of hemoglobin solutions as red cell substitutes.
Ogden JE; Parry ES
Int Anesthesiol Clin; 1995; 33(1):115-29. PubMed ID: 7635553
[TBL] [Abstract][Full Text] [Related]
57. Clinical contextualization and the assessment of adverse events in HBOC trials.
Greenburg AG; Pitman A; Pearce B; Kim HW
Artif Cells Blood Substit Immobil Biotechnol; 2008; 36(6):477-86. PubMed ID: 19039687
[TBL] [Abstract][Full Text] [Related]
58. Haemoglobin-based red cell substitutes: current status.
Ogden JE; Mac Donald SL
Vox Sang; 1995; 69(4):302-8. PubMed ID: 8751299
[TBL] [Abstract][Full Text] [Related]
59. Overview of pathophysiology and rationale for treatment of sickle cell anemia.
Rodgers GP
Semin Hematol; 1997 Jul; 34(3 Suppl 3):2-7. PubMed ID: 9317195
[TBL] [Abstract][Full Text] [Related]
60. PEGylated Bovine Carboxyhemoglobin (SANGUINATE™): Results of Clinical Safety Testing and Use in Patients.
Abuchowski A
Adv Exp Med Biol; 2016; 876():461-467. PubMed ID: 26782246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
